Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial
Nabil F. Saba(Emory University), Christine H. Chung(Moffitt Cancer Center), Mihir R. Patel(Emory University), Aik Choon Tan(Colorado School of Public Health), William A. Stokes(Emory University), Georgia Z. Chen(Emory University), Kedar Kirtane(Moffitt Cancer Center), Asari Ekpenyong(Emory University), Jameel Muzaffar(Moffitt Cancer Center), Nicole C. Schmitt(Emory University), James E. Bates(The University of Texas MD Anderson Cancer Center), Muhammad Zaki Hidayatullah Fadlullah(University of Utah), Kelly R. Magliocca(Emory University), Jill Remick(Emory University), Ritu Chaudhary(Moffitt Cancer Center), Soumon Rudra(Emory University), Yong Teng(Emory University), Conor Steuer(Emory University), Mark W. McDonald(Emory University), Marin Abousaud(Astellas Pharma (United States)), Ashley A. McCook‐Veal(Emory University), Yuan Liu(Emory University), Dong M. Shin(Emory University)
Cited by 76
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Is It Time to Start Transitioning From 2D to 3D Cell Culture?
|Frontiers in Molecular Biosciences|2020|1.6k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926
Head and neck cancer
|The Lancet|2021|829